Key Takeaways:
Anteris Technologies Global Corp. (NASDAQ: AVR) saw its shares gain after securing U.S. Medicare reimbursement for its pivotal 1,000-patient trial, a move that significantly de-risks the regulatory pathway for its next-generation heart valve and challenges incumbent device makers. The decision by the Centers for Medicare & Medicaid Services (CMS) provides crucial funding and is expected to accelerate the study’s timeline.
The company announced Tuesday that procedures in its PARADIGM trial are now eligible for reimbursement under a CMS national coverage policy. This framework, known as Coverage with Evidence Development (CED), allows Medicare to cover the costs of patient care in the trial, removing a major financial and logistical barrier to enrolling patients and activating clinical sites across the United States.
The prospective, randomized controlled trial will enroll approximately 1,000 patients to directly compare the safety and effectiveness of the company’s DurAVR® Transcatheter Heart Valve (THV) against commercially available transcatheter aortic valve replacement (TAVR) devices. The study will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke, and cardiovascular hospitalization at one year post-procedure.
This reimbursement decision follows a significant $320 million capital raise in January 2026, which included a strategic investment from medical device giant Medtronic. Securing CMS coverage is a key execution milestone that leverages that new funding, clearing the path to generate the clinical evidence needed to compete in a TAVR market dominated by Medtronic and Edwards Lifesciences.
Anteris’ lead product, the DurAVR® THV, is a balloon-expandable valve designed to treat aortic stenosis, a life-threatening narrowing of the aortic valve. The company describes it as the first “biomimetic” valve, engineered to mimic the performance of a healthy human aortic valve and restore normal blood flow.
The valve is constructed from a single piece of ADAPT® tissue, Anteris’s patented anti-calcification technology. According to the company, ADAPT® tissue has been used clinically for over a decade in more than 55,000 patients worldwide, providing a long-term track record for the material.
For investors, the CMS decision provides a tangible catalyst by accelerating a pivotal trial that serves as the primary gateway to the lucrative U.S. TAVR market. The head-to-head trial design against established players is ambitious, but a successful outcome could position DurAVR as a disruptive new entrant. One analyst tracked by TipRanks has a "Buy" rating on the stock with a price target of A$13.00. The combination of strong funding, strategic backing from a major industry player, and now a clear, government-funded pathway for its U.S. clinical trial provides Anteris with a much clearer road to potential commercialization.
This article is for informational purposes only and does not constitute investment advice.
